We conducted computational screening of our entire molecule library of more than one million compounds. Existing compounds from our current pipeline and portfolio were also tested as potential treatments for patients. We are involved in the research and development of SARS-CoV-2 antibodies that can neutralize the virus and the development of therapies to prevent blood clots.
Learn more about our ongoing engagement in the fight against COVID-19.